BMO Capital Markets upgraded shares of Precision BioSciences (NASDAQ:DTIL – Free Report) from a market perform rating to an outperform rating in a report released on Friday, Marketbeat Ratings reports ...
Hosted on MSN2d
BMO Capital Upgrades Precision BioSciences (DTIL)Fintel reports that on January 10, 2025, BMO Capital upgraded their outlook for Precision BioSciences (NasdaqCM:DTIL) from ...
Precision BioSciences gains momentum as iECURE reports positive ECUR-506 data, and analysts forecast significant HBV ...
JonesTrading analyst Soumit Roy maintained a Buy rating on Precision BioSciences (DTIL – Research Report) today and set a price target of ...
Is it just market speculation, or is there something more significant unfolding behind the scenes? At the core of Precision BioSciences’ sudden stock surge is the company’s gene-editing technology, ...
BMO Capital upgraded Precision BioSciences (DTIL) to Outperform from Market Perform with an unchanged price target of $34 alter iECURE ...
Precision BioSciences (DTIL) stock saw a 31% premarket surge after positive results from its gene therapy trial for treating ...
Shares of Precision BioSciences, Inc. (NASDAQ: DTIL) soared 60% following the announcement of a complete clinical response in the first infant dosed in a Phase 1/ ...
(RTTNews) - Precision BioSciences, Inc. (DTIL), a clinical-stage gene editing company, on Thursday, announced positive clinical efficacy data from its partner iECURE in the Phase 1/2 OTC-HOPE ...
On Friday, BMO Capital Markets analysts upgraded Precision BioSciences Inc . (NASDAQ: NASDAQ:DTIL) stock rating from Market Perform to Outperform, setting a price target of $34.00. This optimistic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback